The maximum FDA-approved subcutaneous dose is 2.4 mg weekly (Wegovy) for weight management
Prescriptions of the newer anti-hyperglycemic agents continue to stagnate, even among eligible patients [19], which may be related, at least in part, to the uncertainty about the optimal clinical management of T2D
Several developments may change how resets are approached in the coming years
PT-141 Research PT-141 has been investigated for its potential therapeutic effects in treating sexual dysfunction in both men and women
While it is available as a licensed prescription medicine for confirmed carnitine deficiency, over-the-counter supplements occupy a very different regulatory space
doi:10.1155/2012/426130 Dahan, Albert, et al., Targeting the Innate Repair Receptor to Treat Neuropathy. PAIN Reports , vol